Larazotide (Larazotide Acetate, AT-1001, INN-202)

Larazotide acetate is the most clinically advanced drug targeting intestinal tight junction integrity, and it represents a fundamentally different approach to gut health compared to other peptides in this space. While BPC-157 works through growth factors and angiogenesis, and KPV works through anti-inflammatory pathways, larazotide targets the specific molecular mechanism of tight junction disassembly: the zonulin pathway. The story starts with Alessio Fasano's discovery of zonulin in 2000 (PMID: 10875704). Fasano, working at the University of Maryland, identified zonulin as the human equivalent of the Vibrio cholerae zonula occludens toxin (Zot), the bacterial protein that causes the watery diarrhea of cholera by opening intestinal tight junctions. Zonulin, he found, is produced by intestinal epithelial cells in response to certain triggers, including gluten and certain bacteria, and it opens the paracellular pathway by disassembling the tight junction protein complex. This discovery provided the rationale for larazotide: if you could block zonulin's receptor, you could prevent the tight junction from opening, keeping the intestinal barrier intact even in the presence of triggers that would normally increase permeability. The first human study (Paterson et al., PMID: 17305755) was a single-dose trial in celiac patients that confirmed larazotide reduced intestinal permeability (measured by the lactulose/mannitol ratio) during a controlled gluten challenge. The safety profile was essentially indistinguishable from placebo, which makes sense given that the drug isn't absorbed into the bloodstream. The Phase 2b trial (Leffler et al., PMID: 26122079) was more ambitious. It enrolled 342 celiac patients who were on a gluten-free diet but still experiencing symptoms (which happens in 30-50% of celiac patients). The 0.5 mg TID dose reduced symptomatic days by 26% and improved quality of life scores over 12 weeks. Interestingly, the higher doses (1 mg and 2 mg TID) were not more effective, and the 0.5 mg dose showed the clearest benefit, an inverted dose-response that the investigators attributed to the peptide's local mechanism of action. The Phase 3 CeDLara trial was completed, though full results haven't been published yet as of April 2026. The FDA granted Fast Track designation for the celiac disease indication, reflecting the unmet medical need (currently, the only treatment for celiac disease is strict dietary gluten avoidance). Beyond celiac disease, larazotide has theoretical applications wherever increased intestinal permeability plays a pathological role: inflammatory bowel disease, irritable bowel syndrome, type 1 diabetes, multiple sclerosis, and other autoimmune conditions where the "leaky gut" hypothesis is supported by data. Fasano's group has published extensively on the connection between intestinal permeability and autoimmunity, and larazotide is the first drug specifically designed to address this mechanism. The practical limitation today is availability. Larazotide isn't yet FDA approved, and it's available from only a limited number of compounding pharmacies. The cost runs $100-250/month, and sourcing can be inconsistent. For patients specifically seeking tight junction support, it's the most targeted option available, but the more accessible gut-health peptides (BPC-157, KPV) offer alternative mechanisms that may address overlapping clinical goals.